Abstract:Welcome to the latest issue of Seminars in Thrombosis and Hemostasis (STH); this issue primarily devoted to highlighting the contact activation pathway of coagulation. Developed to provide an overview of the current body of knowledge around the roles, applications, and new knowledge of the contact pathway, this compilation serves as an appetizer for the modern thrombosis and inflammation enthusiast. This issue begins with a contribution from Dr. Shamanaev and colleagues, who start at the top of the coagulation cascade and examine the structure and function of coagulation factor XII (FXII), a serine protease, as it relates to disease.[1] The zymogen FXII can convert prekallikrein and factor XI to the proteases kallikrein and activated FXI (FXIa); this process is instrumental in certain disease states to facilitate abnormal incidents like angioedema and thrombotic events. Drawing on its homolog—pro-hepatocyte growth factor activator—a combination of isolated domains was selected for replacement and then assessed for resulting FXII activation and FXIIa activity. This review acts to establish the circulating closed and bound open conformations of FXII that are resistant to and expedite activation, respectively. Such information may prove integral as we proceed to unravel the complexities of key pathological processes in the quest to ultimately develop treatments for thromboinflammatory disorders. The second manuscript in this issue, by Kearney and colleagues, refocuses the spotlight on plasma kallikrein (PKa) and its additional role within the coagulation cascade in directly activating coagulation factor IX (FIX).[2] Three independent studies corroborate a classic canonical intrinsic pathway (FXII–FXI–FIX) and a noncanonical pathway (PKa–FIX). With the existence of PKa as a coagulation clotting factor established, the next step is the investigation of the products of its cleavage as it relates to the functioning of the body. This manuscript will eventually inform on novel anticoagulant compounds to be researched, tested, and developed for future use. In the third manuscript, Dr. Lira and colleagues shift our attention to coagulation factor XI (FXI)—a zymogen of plasma protease FXIa, which is key in facilitating normal physiological functions and driving some abnormal pathological processes.[3] On top of sharing a convergence history, mirroring PKa, FXI has also been demonstrated to play additional roles, in this case, promoting the generation of thrombin, lending to its versatility in function. Furthermore, FXI activity ventures beyond the intrinsic pathway of coagulation into the world of platelets, endothelial cells, and inflammation. This work summarizes FXI's many responsibilities and informs potential future research directions targeting FXI as a focus for therapeutic intervention. The fourth manuscript, by Vappala and colleagues, highlights fundamental triggers of the contact pathway of coagulation: polyphosphates, DNA, and RNA.[4] More specifically, extracellular DNA in the form of neutrophil extracellular traps (NETs) have been identified as advancing the occurrence and severity of thrombotic events. From that standpoint, this article explores the understood functions of extracellular polyphosphate and nucleic acids in thrombosis, and it ponders the notion of engineering innovative agents designed to target the prothrombotic activities linked to polyphosphate and NETs. Dr. Petersen and colleagues follow with discussion of the C1-inhibitor, which is a vital regulator of the intrinsic coagulation pathway, fibrinolytic system, and complement cascade.[5] The critical loss in level and function of the C1-inhibitor, resulting from a mutation in the SERPING1 gene, gives rise to the rare, genetic disorder known as hereditary angioedema, a condition severely debilitating to patients. Furthermore, C1-inhibitor deficiency is associated with activation of the contact activation cascade and kallikrein–kinin pathway, resulting in undesired vascular leakage. The authors tell the story of hereditary angioedema from the clinical presentation to biological processes, concluding in management options to improve the quality of life for impacted individuals. The final manuscript under the theme of contact activation, by Goel and colleagues, considers a prominent complication of anticoagulant therapy linked to the severity of subsequent bleeding incidents.[6] As such, it is imperative to strike that delicate balance between hemostasis and hemorrhage and especially so for the subset of patients utilizing medical devices, such as extracorporeal devices and central venous catheters. Viable targets for future investigation include FXI, FXII, and prekallikrein, for selective inhibition of these steps within the contact pathway does not overtly affect normal hemostasis. This review consolidates the latest in vivo and clinical data that -Abstract Truncated-

A Brief History of Hemostasis and Thrombosis at the Mayo Clinic

Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part IV

Greats in the History of Thrombosis and Hemostasis

Development of a Coagulation Disorders Unit

50 Years of Pediatric Hemostasis: Knowledge, Diagnosis, and Treatment

An Update on Safe Anticoagulation.

Blood Coagulation: Hemostasis and Thrombin Regulation

Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis

Innovative Diagnostic Solutions in Hemostasis

Targeting the Contact Pathway of Coagulation for the Prevention and Management of Medical Device-Associated Thrombosis

Contact Activation: Where Thrombosis and Hemostasis Meet on a Foreign Surface, Plus a Mini-editorial Compilation ("Part XVI")

Hemostasis Testing in the Emergency Department: A Narrative Review

A Critical Reappraisal of the Bleeding Time

Laboratory Diagnostics for Thrombosis and Hemostasis Testing—Part 3

Mechanisms Involved in Regulation of Blood Coagulation: History of Research and Perspectives

Evolution of Hemostasis Testing: A Personal Reflection Covering over 40 Years of History

A career in solving clinical‐pathological conundrums: Heyde syndrome, anti‐platelet factor 4 disorders, and microvascular limb ischemic necrosis

Hemostats in the clinic

Navigating Critical Waters: The Importance of a Systematic Coagulation Algorithm in the Intensive Care Unit

Cardiovascular disease and thrombosis: Intersections with the immune system, inflammation, and the coagulation system

Adjuncts to Blood Component Therapies for the Treatment of Bleeding in the Intensive Care Unit